CN102218078B - 一种含有蒙脱石的利福昔明混悬液及其制备方法 - Google Patents
一种含有蒙脱石的利福昔明混悬液及其制备方法 Download PDFInfo
- Publication number
- CN102218078B CN102218078B CN201110097527A CN201110097527A CN102218078B CN 102218078 B CN102218078 B CN 102218078B CN 201110097527 A CN201110097527 A CN 201110097527A CN 201110097527 A CN201110097527 A CN 201110097527A CN 102218078 B CN102218078 B CN 102218078B
- Authority
- CN
- China
- Prior art keywords
- rifaximin
- suspension
- water
- montmorillonitum
- suspending agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims abstract description 78
- 229960003040 rifaximin Drugs 0.000 title claims abstract description 77
- 239000000725 suspension Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title abstract description 12
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 title abstract description 6
- 229910052901 montmorillonite Inorganic materials 0.000 title abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000375 suspending agent Substances 0.000 claims abstract description 17
- 239000004094 surface-active agent Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 230000001954 sterilising effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000001433 sodium tartrate Substances 0.000 claims description 3
- 229960002167 sodium tartrate Drugs 0.000 claims description 3
- 235000011004 sodium tartrates Nutrition 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 244000144977 poultry Species 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 244000144972 livestock Species 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000003287 bathing Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 32
- 239000003814 drug Substances 0.000 description 29
- 241000287828 Gallus gallus Species 0.000 description 20
- 235000013330 chicken meat Nutrition 0.000 description 19
- 229940079593 drug Drugs 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 241000282887 Suidae Species 0.000 description 5
- 235000021053 average weight gain Nutrition 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000273 veterinary drug Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940079866 intestinal antibiotic Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229940062280 rifamycin sodium Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- -1 sugar coating sheet Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
项目 | 混悬情况 | 沉降体积比 |
1分钟 | 分散良好 | 0.95 |
30分钟 | 分散良好 | 0.95 |
1小时 | 分散良好 | 0.95 |
3小时 | 分散良好 | 0.94 |
药品 | 0个月 | 1个月 | 2个月 | 3个月 | 6个月 |
实施例1 | 101±0.20 | 100±0.15 | 100±0.22 | 99±0.16 | 98±0.23 |
实施例2 | 50±0.14 | 49±0.08 | 49±0.16 | 49±0.12 | 48±0.20 |
实施例3 | 151±0.06 | 150±0.16 | 150±0.11 | 149±0.21 | 149±0.18 |
对照药品 | 79±0.31 | 78±0.21 | 77±0.18 | 77±0.24 | 75±0.26 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110097527A CN102218078B (zh) | 2011-04-19 | 2011-04-19 | 一种含有蒙脱石的利福昔明混悬液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110097527A CN102218078B (zh) | 2011-04-19 | 2011-04-19 | 一种含有蒙脱石的利福昔明混悬液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102218078A CN102218078A (zh) | 2011-10-19 |
CN102218078B true CN102218078B (zh) | 2012-10-10 |
Family
ID=44774949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110097527A Expired - Fee Related CN102218078B (zh) | 2011-04-19 | 2011-04-19 | 一种含有蒙脱石的利福昔明混悬液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102218078B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721325B (zh) * | 2017-04-13 | 2020-03-06 | 辽宁大熊制药有限公司 | 蒙脱石混悬液及其制备方法 |
CN106943349B (zh) * | 2017-04-21 | 2020-12-11 | 华南农业大学 | 一种泰地罗新混悬注射液及其制备方法 |
CN110623929A (zh) * | 2019-09-17 | 2019-12-31 | 南京臣功制药股份有限公司 | 一种利福昔明干混悬剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1485034A (zh) * | 2002-09-26 | 2004-03-31 | 天津合益达生物医学技术有限公司 | 利福昔明干混悬颗粒剂 |
CN101642439A (zh) * | 2009-08-17 | 2010-02-10 | 扬州市三药制药有限公司 | 利福昔明干混悬剂及其生产方法 |
CN101836959A (zh) * | 2010-05-20 | 2010-09-22 | 山东达因海洋生物制药股份有限公司 | 一种制备几乎无苦味利福昔明干混悬剂的方法 |
-
2011
- 2011-04-19 CN CN201110097527A patent/CN102218078B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1485034A (zh) * | 2002-09-26 | 2004-03-31 | 天津合益达生物医学技术有限公司 | 利福昔明干混悬颗粒剂 |
CN101642439A (zh) * | 2009-08-17 | 2010-02-10 | 扬州市三药制药有限公司 | 利福昔明干混悬剂及其生产方法 |
CN101836959A (zh) * | 2010-05-20 | 2010-09-22 | 山东达因海洋生物制药股份有限公司 | 一种制备几乎无苦味利福昔明干混悬剂的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102218078A (zh) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Synergy of Astragalus polysaccharides and probiotics (Lactobacillus and Bacillus cereus) on immunity and intestinal microbiota in chicks | |
CN103989728B (zh) | 一种含有含珠草和β‑内酰胺类抗菌药的畜禽用复方药物 | |
CN105685970A (zh) | 一种全消化道改善的复合营养食品 | |
CN104870002A (zh) | 用于预防和/或治疗寄生虫病的甲壳素或其衍生物 | |
CN103933086A (zh) | 一种含穿心莲和阿米卡星的畜禽用复方药物 | |
CN103977089B (zh) | 一种含有赤芍和磷霉素的畜禽用复方药物 | |
CN104171743B (zh) | 一种肉鸡用饲料添加剂及其制备方法 | |
CN102218078B (zh) | 一种含有蒙脱石的利福昔明混悬液及其制备方法 | |
CN103948692B (zh) | 一种含有赤芍和阿米卡星的畜禽用复方药物 | |
CN103989730A (zh) | 一种含有含珠草和氟喹诺酮类抗菌药的畜禽用复方药物 | |
CN103989729A (zh) | 一种含有含珠草和磺胺间甲氧嘧啶钠的畜禽用复方药物 | |
CN104306420A (zh) | 一种含有大风艾和磺胺间甲氧嘧啶钠的畜禽用复方药物 | |
CN104435069B (zh) | 一种提高猪免疫功能的兽药组合物、应用及其制备方法 | |
CN107752015A (zh) | 一种全消化道改善的复合营养食品 | |
CN102614294A (zh) | 一种复方阿莫西林混悬注射剂及其制备方法 | |
CN104337847A (zh) | 一种含有凤尾草和磷霉素的畜禽用复方药物 | |
KR20130096088A (ko) | 백지 추출물을 유효성분으로 함유하는 장출혈성 대장균 감염증의 예방 또는 치료용 약학 조성물 | |
CN106318887A (zh) | 一种spf鸡肠道微生态制剂及制备方法和应用 | |
CN111821322A (zh) | 一种可替代抗生素的禽用微生态口服制剂及其应用 | |
CN104435038A (zh) | 一种含有大风艾和痢菌净的畜禽用复方药物 | |
KR101348177B1 (ko) | 패장 추출물을 유효성분으로 함유하는 장출혈성 대장균 감염증의 예방 또는 치료용 약학 조성물 | |
CN117264910B (zh) | 耐高温广谱沙门氏菌的噬菌体及其临床应用 | |
Wagner et al. | Decontamination of gnotobiotic mice experimentally monoassociated with Candida albicans | |
RU2471359C1 (ru) | Способ коррекции иммунобиологических показателей у поросят в период отъема | |
CN103948657A (zh) | 一种含穿心莲和β-内酰胺类抗菌药的畜禽用复方药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING AILIBI VETERINARY DRUG INSTITUTE CO., LTD. Free format text: FORMER OWNER: NANJING WEITAI FAMA VETERINARY RESEARCH INSTITUTE CO., LTD. Effective date: 20150810 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150810 Address after: Weigang Xuanwu District of Nanjing in Jiangsu province No. 1 Nanjing Agricultural University 210095 Patentee after: Nanjing Aili Veterinary Research Institute Co.,Ltd. Address before: Xuanwu District of Nanjing City, Jiangsu province 210095 Nanjing Agricultural University Wei Tong Road No. 6 Patentee before: NANJING WEITAI FAMA VETERINARY RESEARCH INSTITUTECO., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170516 Address after: Weigang Xuanwu District of Nanjing 210095 Jiangsu province No. 1 Nanjing Agricultural University Animal Medical College Patentee after: Nanjing Jing Heng Heng Pharmaceutical Technology Co.,Ltd. Address before: Weigang Xuanwu District of Nanjing 210095 Jiangsu province Nanjing Agricultural University No. 1 Nanjing Welbon ipharma Veterinary Research Institute Co Ltd Patentee before: Nanjing Aili Veterinary Research Institute Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Nanjing Aili Veterinary Research Institute Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190530 Address after: 211131 Xi1, Xi2 and Xi3 in the production base of Tangshan Industrial Concentration Zone, Jiangning District, Nanjing City, Jiangsu Province Patentee after: Nanjing Jiangsu Nongda Animal Pharmaceutical Co.,Ltd. Address before: 210095 School of Animal Medicine, Nanjing Agricultural University, No. 1 Weigang, Xuanwu District, Nanjing, Jiangsu Province Patentee before: Nanjing Jing Heng Heng Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210421 Address after: Room G03, 1110, 11 / F, building 2, Xinghuo Zhongchuang space, Nanjing National Agricultural Innovation Park, 20 Yuhe Road, Pukou District, Nanjing City, Jiangsu Province, 210000 Patentee after: Jiangsu Jiyu Biomedical Technology Co.,Ltd. Address before: 211131 Xi1, Xi2 and Xi3 in the production base of Tangshan Industrial Concentration Zone, Jiangning District, Nanjing City, Jiangsu Province Patentee before: Nanjing Jiangsu Nongda Animal Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121010 |
|
CF01 | Termination of patent right due to non-payment of annual fee |